Navigation Links
Scientists favor needles over tablets for global vaccinations
Date:4/26/2010

chronic parasitic infections can derail vaccination programs that are effective in healthy individuals.

Because only bystander cells in the same lymph node as those responding to the parasite infection are affected by active cytokines, this study suggests that people infected with gastrointestinal worms may respond better to vaccines injected under the skin than those given by mouth. This is critical information for the development of globally-effective vaccination strategies.

Although the current study will not necessarily lead to improved treatments for worm infections themselves, by understanding how worm infection affects other immune responses, scientists may be able to improve the efficacy of ordinary vaccines like those used to prevent polio, measles, malaria and TB in those regions of the world where most children are already infected with parasitic worms prior to receiving their childhood immunizations.


'/>"/>

Contact: Brian Turner
bturner@trudeauinstitute.org
518-891-3080
Trudeau Institute
Source:Eurekalert  

Page: 1 2

Related biology news :

1. Phosphorous in sodas and processed foods accelerates signs of aging say Harvard scientists
2. Scientists crack code of critical bacterial defense mechanism
3. Scientists discover key step for regulating embryonic development
4. Scientists sever molecular signals that prolific parasite uses to puppeteer cells
5. Scientists create artificial human skin with biomechanical properties using tissue engineering
6. Brown scientists elected to American Academy of Arts and Sciences
7. Scripps Research scientists reveal how genetic mutations may cause type 1 diabetes
8. 2 Hopkins scientists awarded European honorary doctorates
9. Chinese scientists discover marker indicating the developmental potential of stem cells
10. Scientists find new genes for cancer, other diseases in plants, yeast and worms
11. Scripps Research scientists solve mystery of fragile stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Scientists favor needles over tablets for global vaccinations
(Date:8/6/2015)... 2015  Today, U.S. Congressman Mike Honda ... to learn firsthand how Silicon Valley technologies can ... a world leader in multi-factor identity management and ... federal agencies and commercial organizations achieve new levels ... "The vast majority of network breaches can be ...
(Date:8/5/2015)... August 5, 2015 Transparency Market ... Recognition Market - Global Industry Analysis, Size, Share, Growth, ... for facial recognition is forecast to reach US$ 2,671.8 ... demand for surveillance systems by civil and government agencies. ... crimes and terrorist activities across the globe that would ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6
... at the Smithsonian,s National Zoo detected a secondary rise ... panda Mei Xiang (may-SHONG) earlier this month. The results ... to believe the hormone rise indicates that it would ... birth to a cub or comes to the end ...
... 20, 2008) The future of high-intensity x-ray science ... Department of Energy,s Argonne National Laboratory have devised a ... free electron laser oscillator (X-FELO) we are proposing can ... than currently operating machines," Argonne Distinguished fellow Kwang-Je Kim ...
... as temperatures warm along the East Coast of the ... less likely they are to keep pace with the ... the Manomet Center for Conservation Sciences analyzed changes in ... birds along the coast of eastern Massachusetts since 1970. ...
Cached Biology News:A novel X-ray source could be brightest in the world 2Birds migrate earlier, but some may be left behind as the climate warms rapidly 2
(Date:9/1/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... of Directors as a Non-Executive Director. Sara will also be ... the Shire Board. Both appointments will be effective as of ... President and Chief Executive Officer of Dun & Bradstreet, Inc. ... D&B, she helped drive the transformation of the company from ...
(Date:8/31/2015)... 2015 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX) ... Company,s lead antibody, HuMab 5B1, will be garnering major ... the upcoming World Molecular Imaging Congress (WMIC) being held ... Researchers from the Department of Radiology at Memorial Sloan ... use of MabVax,s lead antibody as a PET imaging ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has announced the ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Middle East & Africa Biomedical Sensors ... a CAGR of 3.26% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:8/31/2015)... 31, 2015  US-Australian drug discovery company, Novogen ... confirmed its comprehensive scientific review has identified high ... areas of unmet patient need. Novogen is moving ... projects prior to entering into Phase 1 clinical ... Acting Chief Executive Officer, Iain Ross , ...
Breaking Biology Technology:Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... , , ... Corporation (Pink Sheets: CGCP), a market leader in laser transmyocardial ... (Investigational Device Exemption) to the Food and Drug Administration to ... with refractory angina. The PHOENIX Combination Delivery System combines ...
... TAINAN, Taiwan, July 30 /PRNewswire-Asia/ -- Eli Lilly ... today that they have,reached an amicable resolution of ... ScinoPharm,s manufacture and sale of gemcitabine,hydrochloride around the ... of the settlement, Lilly has granted ScinoPharm a ...
... LAUSANNE, Switzerland and MEDFORD, Massachussets, July 30 ... companies with a focus on the development of ... Protein Technologies (MSM), a human,antibody drug discovery company ... announce the signature of an exclusive,agreement for the ...
Cached Biology Technology:Cardiogenesis Corporation Makes Pre-IDE Submission for PHOENIX Combination Delivery System 2Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 2Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 3Debiopharm and MSM Protein Technologies Sign Agreement for Research and Development of Debio 0929, a Novel Oncology Biologic 4